Prescient Therapeutics CEO highlights PTX-100 progress in RAS-Driven cancer trial

In this HotCopper Capital Compass interview, Prescient Therapeutics (ASX: PTX) CEO James McDonnell discusses the company’s progress with PTX-100, a first-in-class therapy targeting the RAS pathway in cancer.

Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.

McDonnell outlines encouraging Phase 2A results in cutaneous T-cell lymphoma, the FDA fast track designation, and the broader potential of PTX-100 in addressing a significant unmet need across multiple cancer types.

Join the discussion: See what HotCopper users are saying about Prescient Therapeutics and be part of the conversations that move the markets.

The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.